Summary:

NameEndometrial cancer (A:m6A)
Description~70% of tumor samples from endometrial cancer patients exhibited decreased m6A levels due to either decreased expression of METTL3 or loss of function mutation in METTL14 (R298P). This generates a reduction in m6A mRNA methylation levels and an enhancement in proliferation and tumorigenicity. Reductions in m6A methylation lead to decreased expression of the negative AKT regulator PHLPP2 and increased expression of the positive AKT regulator mTORC2. Increased AKT activation is one of the main mediators of increased proliferation in cells.
Related RNA reactionA:m6A
Found in RNAmRNA
Modified TranscriptAkt signaling
Mapping TechnologyMeRIP-seq
Quantification techniquesMeRIP-RT-qPCR, LC-MS/MS

Enzymes connected to this disease:

Acronym Full name Enzyme Role Organism
METTL3 N6-adenosine-methyltransferase 70 kDa subunit tumor-suppressor Homo sapiens
 

Publications:

ID Title Authors Journal Details PubMed Id DOI
1012 mA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Jun Liu Nat Cell Biol [details] 30154548 10.1038/s41556-018-0174-4

Copyright © Genesilico - All rights reserved
If you have any advice or suggestions for corrections or improvements, please contact: Andrea Cappannini - lp.vog.bcmii@ininnappaca